Abstract
In this study we characterised the effects of a low frequency variant in the TYK2 gene known to be protective to over 10 immune-mediated diseases. By interrogating data available through the UK Biobank we found that people carrying the protective TYK2 variant were no more likely to have serious infections or to develop cancer than people without the variant; suggesting TYK2 as a potential therapeutic target with few side effects.